deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02316834

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (POSITION)

POSITION: A Pilot Study of Induction PARP Inhibition in Ovarian Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Fallopian Tube Serous Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Ovarian Mass Primary Peritoneal Serous Adenocarcinoma Stage III Fallopian Tube Cancer AJCC v7 Stage III Ovarian Cancer AJCC v6 and v7 Stage III Primary Peritoneal Cancer AJCC v7 Stage IIIA Fallopian Tube Cancer AJCC v7 Stage IIIA Ovarian Cancer AJCC v6 and v7 Stage IIIA Primary Peritoneal Cancer AJCC v7 Stage IIIB Fallopian Tube Cancer AJCC v7 Stage IIIB Ovarian Cancer AJCC v6 and v7 Stage IIIB Primary Peritoneal Cancer AJCC v7 Stage IIIC Fallopian Tube Cancer AJCC v7 Stage IIIC Ovarian Cancer AJCC v6 and v7 Stage IIIC Primary Peritoneal Cancer AJCC v7 Stage IV Fallopian Tube Cancer AJCC v6 and v7 Stage IV Ovarian Cancer AJCC v6 and v7 Stage IV Primary Peritoneal Cancer AJCC v7
Interventions BMN 673 Laboratory Biomarker Analysis
Updated 12 times since 2017 Last updated: Feb 11, 2022 Started: Jun 2, 2015 Primary completion: Jan 14, 2022 Completion: Jan 14, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Fallopian Tube Serous Adenocarcinoma and High Grade Ovarian Serous Adenocarcinoma and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~May 2017 · 3 months · monthly snapshotActive Not Recruiting~May 2017 – ~Mar 2018 · 10 months · monthly snapshotActive Not Recruiting~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotActive Not Recruiting~Oct 2018 – ~Jul 2019 · 9 months · monthly snapshotActive Not Recruiting~Jul 2019 – ~Jun 2020 · 11 months · monthly snapshotActive Not Recruiting~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshotActive Not Recruiting~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  3. Mar 2022 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

    Status: Active Not Recruiting → Completed

  4. Jan 2021 — Mar 2022 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting EARLY_PHASE1

▶ Show 7 earlier versions

  1. Jul 2019 — Jun 2020 [monthly]

    Active Not Recruiting EARLY_PHASE1

  2. Oct 2018 — Jul 2019 [monthly]

    Active Not Recruiting EARLY_PHASE1

  3. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting EARLY_PHASE1

  4. Mar 2018 — Jun 2018 [monthly]

    Active Not Recruiting EARLY_PHASE1

  5. May 2017 — Mar 2018 [monthly]

    Active Not Recruiting EARLY_PHASE1

  6. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting EARLY_PHASE1

    Phase: Phase 0 → EARLY_PHASE1

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting Phase 0

    First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations